Abstract
Along with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive and important place in the treatment of HIV-1 infections, and are in rapid development. These compounds can be grouped into two classes: the first generation NNRTIs, mainly discovered by random screening, and the second generation NNRTIs, developed as a result of comprehensive strategies involving molecular modelling, rationale-based drug synthesis, biological and pharmacokinetic evaluations. The recent boom of NNRTIs is mainly due to their antiviral potency, high specificity and low toxicity. The rapid emergence of drug-resistant HIV-1 strains induced by the first generation drugs is a disadvantage bypassed, in part, by the broad spectrum second generation NNRTIs. Starting from the first generation, this review will focus on the second generation NNRTIs dealing with the recent and most interesting published results, highlighting the guidelines for the development of a third generation of NNRTIs.
Keywords: Non-nucleoside hiv-1 reverse transcriptase (rt) inhibitors, Nucleoside reverse transcriptase inhibitors(nrtis), Protease inhibitors(pls), hept, Tsao-t, Tsao-t analogues, Dabo antiviral agents, Dihydroalkoxybenzyloxypyrimidines(dabo), Benzodiazepinones(tibo)
Current Pharmaceutical Design
Title: Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives
Volume: 8 Issue: 8
Author(s): Giuseppe Campiani, Anna Ramunno, Giovanni Maga, Vito Nacci, Caterina Fattorusso, Bruno Catalanotti, Elena Morelli and Ettore Novellino
Affiliation:
Keywords: Non-nucleoside hiv-1 reverse transcriptase (rt) inhibitors, Nucleoside reverse transcriptase inhibitors(nrtis), Protease inhibitors(pls), hept, Tsao-t, Tsao-t analogues, Dabo antiviral agents, Dihydroalkoxybenzyloxypyrimidines(dabo), Benzodiazepinones(tibo)
Abstract: Along with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive and important place in the treatment of HIV-1 infections, and are in rapid development. These compounds can be grouped into two classes: the first generation NNRTIs, mainly discovered by random screening, and the second generation NNRTIs, developed as a result of comprehensive strategies involving molecular modelling, rationale-based drug synthesis, biological and pharmacokinetic evaluations. The recent boom of NNRTIs is mainly due to their antiviral potency, high specificity and low toxicity. The rapid emergence of drug-resistant HIV-1 strains induced by the first generation drugs is a disadvantage bypassed, in part, by the broad spectrum second generation NNRTIs. Starting from the first generation, this review will focus on the second generation NNRTIs dealing with the recent and most interesting published results, highlighting the guidelines for the development of a third generation of NNRTIs.
Export Options
About this article
Cite this article as:
Campiani Giuseppe, Ramunno Anna, Maga Giovanni, Nacci Vito, Fattorusso Caterina, Catalanotti Bruno, Morelli Elena and Novellino Ettore, Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives, Current Pharmaceutical Design 2002; 8 (8) . https://dx.doi.org/10.2174/1381612024607207
DOI https://dx.doi.org/10.2174/1381612024607207 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microcirculatory Endothelial Dysfunction During Endotoxemia - Insights into Pathophysiology, Pathologic Mechanisms and Clinical Relevance
Current Vascular Pharmacology The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Is there a Role for Cortisol in the Accumulation of Lipids in the Intima a Crucial Step of Atherogenesis?
Current Vascular Pharmacology DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews What does the Hospital Anxiety and Depression Scale (HADS) Really Measure in Liaison Psychiatry Settings?
Current Psychiatry Reviews Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Nutraceuticals and Bio-inspired Materials from Microalgae and their Future Perspectives
Current Topics in Medicinal Chemistry Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy